Integrating with previously identified polygenic risk scores for asthma and drug-target enrichment identified seven robust genes including <i>MPO</i> , <i>CHCHD3, CACNA1S, PI4KA, EP400, CREBBP</i> and <i>KCNA10</i> with known associations as biomarkers for asthma severity and drug targets for airway inflammation.<h4>Conclusions</h4>Epigenetic variability from birth through puberty provides mechanistic insights into fetal programming of developmental and immune pathways associated with lung function. This evidence concerns the gene MPO and asthma.